Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Risk of Prostate Cancer Death in the PLCO Cohort Based on a Four Kallekrein Panel

Principal Investigator
Name
Jonathan Shoag
Degrees
M.D.
Institution
Case Western Reserve University
Position Title
Assistant Professor, Department of Urology, School of Medicine
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-912
Initial CDAS Request Approval
Feb 16, 2022
Title
Risk of Prostate Cancer Death in the PLCO Cohort Based on a Four Kallekrein Panel
Summary
Baseline PSA has long been used as a screening and risk assessment tool in men with suspected or confirmed prostate cancer. The goal of this project is to evaluate the association between a four kallikrein panel (total PSA, free PSA, intact PSA, and human kallikrein-related peptidase 2) and prostate cancer mortality for patients in the PLCO Cohort and compare the predictive power of the four kallikrein score with that of baseline PSA.
Aims

- Evaluate the predictive power of a four kallikrein panel for prostate cancer specific mortality

Collaborators

N/A